HPV vaccination in Africa in the COVID-19 era: a cross-sectional survey of healthcare providers' knowledge, training, and recommendation practices.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2024
Historique:
received: 22 11 2023
accepted: 02 01 2024
medline: 2 2 2024
pubmed: 1 2 2024
entrez: 1 2 2024
Statut: epublish

Résumé

Although the burden of cervical cancer in Africa is highest, HPV vaccination coverage remains alarmingly low in this region. Providers' knowledge and recommendation are key drivers of HPV vaccination uptake. Yet, evidence about providers' knowledge and recommendation practices about the HPV vaccine against a backdrop of emerging vaccine hesitancy fueled by the COVID-19 pandemic is lacking in Africa. A cross-sectional study was conducted in 2021-2022 among healthcare providers involved in cervical cancer prevention activities in Africa. They were invited to report prior training, the availability of the HPV vaccine in their practice, whether they recommended the HPV vaccine, and, if not, the reasons for not recommending it. Their knowledge about the HPV vaccine was assessed through self-reporting (perceived knowledge) and with three pre-tested knowledge questions (measured knowledge). Of the 153 providers from 23 African countries who responded to the survey (mean age: 38.5 years, SD: 10.1), 75 (54.0%) were female and 97 (63.4%) were based In countries with national HPV immunization programs. Overall, 57 (43.8%) reported having received prior training on HPV vaccine education/counseling, and 40 (37.4%) indicated that the HPV vaccine was available at the facility where they work. Most respondents (109, 83.2%) reported recommending the HPV vaccine in their practice. Vaccine unavailability (57.1%), lack of effective communication tools and informational material (28.6%), and need for adequate training (28.6%) were the most commonly reported reasons for not recommending the HPV vaccine. While 63 providers (52.9%) reported that their knowledge about HPV vaccination was adequate for their practice, only 9.9% responded correctly to the 3 knowledge questions. To increase HPV vaccination coverage and counter misinformation about this vaccine in Africa, adequate training of providers and culturally appropriate educational materials are needed to improve their knowledge of the HPV vaccine and to facilitate effective communication with their patients and the community.

Identifiants

pubmed: 38299075
doi: 10.3389/fpubh.2024.1343064
pmc: PMC10829043
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1343064

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Informations de copyright

Copyright © 2024 Fokom Domgue, Dille, Kapambwe, Yu, Gnangnon, Chinula, Murenzi, Mbatani, Pande, Sidibe, Kamgno, Traore, El Fazazi, Diop, Tebeu, Diomande, Lecuru, Adewole, Plante, Basu, Dangou and Shete.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cochrane Database Syst Rev. 2020 Jan 17;1:CD011895
pubmed: 31978259
Lancet Glob Health. 2023 Jan;11(1):e28-e29
pubmed: 36521948
Vaccine. 2018 Aug 6;36(32 Pt A):4823-4829
pubmed: 29807710
JAMA Netw Open. 2022 Nov 1;5(11):e2240801
pubmed: 36346631
Front Public Health. 2022 Mar 21;10:802947
pubmed: 35387182
Hum Vaccin Immunother. 2018;14(10):2355-2357
pubmed: 29617173
Hum Vaccin Immunother. 2023 Aug 1;19(2):2219185
pubmed: 37340826
BMC Cancer. 2019 Jun 11;19(1):563
pubmed: 31185951
Health Policy Plan. 2020 Jul 1;35(6):701-717
pubmed: 32538437
Front Public Health. 2015 Nov 26;3:269
pubmed: 26636066
BMC Public Health. 2020 Feb 4;20(1):171
pubmed: 32019543
Vaccine. 2013 Dec 29;31 Suppl 5:F32-46
pubmed: 24331746
Prev Med. 2021 Mar;144:106399
pubmed: 33388322
Clin Exp Vaccine Res. 2022 May;11(2):149-154
pubmed: 35799873
Glob Health Res Policy. 2022 Jul 19;7(1):21
pubmed: 35850783
Lancet Glob Health. 2019 Jan;7(1):e20-e21
pubmed: 30514615
Vaccine. 2018 Aug 6;36(32 Pt A):4761-4767
pubmed: 29580641
BMC Public Health. 2023 May 26;23(1):974
pubmed: 37237329
Vaccine. 2020 May 19;38(24):4001-4005
pubmed: 32336599
JAMA Pediatr. 2018 May 7;172(5):e180016
pubmed: 29507952
Prev Med. 2021 Jul;148:106554
pubmed: 33857561
EClinicalMedicine. 2021 Apr 17;34:100836
pubmed: 33997733
Wkly Epidemiol Rec. 2009 Apr 10;84(15):118-31
pubmed: 19360985
Lancet Glob Health. 2023 Jul;11(7):e1096-e1104
pubmed: 37207683
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
Front Public Health. 2023 Jul 11;11:1203610
pubmed: 37497028

Auteurs

Joel Fokom Domgue (J)

Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaoundé, Cameroon.
Department of Gynecology and Obstetrics, Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaoundé, Cameroon.
Centre Inter-Etats d'Enseignement Supérieur en Santé Publique d'Afrique Centrale, Brazzaville, Republic of Congo.

Issimouha Dille (I)

Division of Noncommunicable Diseases, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.

Sharon Kapambwe (S)

Division of Noncommunicable Diseases, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.

Robert Yu (R)

Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Freddy Gnangnon (F)

Division of Surgical Oncology, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.

Lameck Chinula (L)

University of North Carolina Project-Malawi, Lilongwe, Malawi.
Division of Global Women's Health, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Gad Murenzi (G)

Einstein-Rwanda Research and Capacity Building Program, Rwanda Military Hospital, Kigali, Rwanda.
Department of Pathology, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

Nomonde Mbatani (N)

Gynecologic Oncology Unit, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Mala Pande (M)

Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Fatoumata Sidibe (F)

Medical Oncology Unit, CHU du Point G, Faculty of Medicine and Dentistry, University of Bamako, Bamako, Mali.

Joseph Kamgno (J)

Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaoundé, Cameroon.

Bangaly Traore (B)

Division of Surgical Oncology, Faculty of Health Sciences and Technics, University Gamal Abdel Nasser of Conakry, Conakry, Guinea.

Hicham El Fazazi (HE)

Department of Gynecology and Obstetrics, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.

Mamadou Diop (M)

Institut du Cancer Joliot Curie, CHU Aristide Le Dantec, Dakar, Senegal.

Pierre-Marie Tebeu (PM)

Department of Gynecology and Obstetrics, Faculty of Medicine and Biomedical Sciences, University of Yaounde, Yaoundé, Cameroon.
Centre Inter-Etats d'Enseignement Supérieur en Santé Publique d'Afrique Centrale, Brazzaville, Republic of Congo.

Mohenou Isidore Diomande (MI)

Department of Pathology, University Teaching Hospital of Cocody, Abidjan, Côte d'Ivoire.

Fabrice Lecuru (F)

Department of Gynecologic and Breast Surgical Oncology, Institut Curie, Paris, France.

Isaac Adewole (I)

Department of Obstetrics and Gynecology, Faculty of Clinical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria.

Marie Plante (M)

Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Laval University, Québec City, QC, Canada.

Partha Basu (P)

Screening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, Lyon, France.

Jean-Marie Dangou (JM)

Division of Noncommunicable Diseases, World Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.

Sanjay Shete (S)

Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH